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1.  INTRODUCTION
Lung cancer is a rising epidemic and remains the 
leading cause of cancer death in both men and women 
in Canada 1. In general, 500 Canadians are diagnosed 
with and 400 Canadians die of lung cancer every 
week 1. Such high morbidity and mortality in patients 
with primary lung cancer emphasizes the need for 
palliative treatment intent.
Morbidity from lung cancer or lung metastases 
often presents as troublesome thoracic symptoms 
such as hemoptysis, cough, chest pain, and dyspnea. 
Palliative radiotherapy has been effective in amelio-
rating these symptoms 2–4 and improves or preserves 
the quality of life (q o l ) remaining in approximately 
one third of affected patients 5.
In the past, clinical trials in patients with lung 
cancer have focused on traditional endpoints such 
as overall survival, disease-free survival, or local 
control 6. Given the relatively poor prognosis of 
patients with locally advanced lung cancer or lung 
metastases, the inclusion of q o l  as a primary endpoint 
of treatment becomes increasingly important. Quality 
of life encompasses the minimization of risks and 
maximization of benefits of a treatment, including 
physical and psychosocial effects on the well-being 
of patients 7. Studying q o l  is particularly relevant in 
the field of palliative radiotherapy because of known 
treatment-related side effects and toxicities.
Few studies focus on q o l  and symptom palliation 
as primary endpoints. The purpose of the present 
review was to accurately assess the recent use of q o l  
tools in trials that evaluated the efficacy of palliative 
radiotherapy in patients with lung cancer or lung 
metastases.
2.  METHODS
2.1  Search Strategy
We conducted a literature review using the m e d l i n e  
(Ovid) database for 1950 to February 2008. Key 
terms such as “lung cancer,” “lung neoplasms,” or 
“lung metastases” were combined with the terms 
ABSTRACT
Approximately 27% of North American cancer deaths 
are attributable to cancer of the lung. Many lung 
cancers are found at an advanced stage, rendering the 
tumours inoperable and the patients palliative. Com-
mon symptoms associated with palliative lung cancer 
include cough, hemoptysis, and dyspnea, all of which 
can significantly debilitate and diminish quality of life 
(q o l ). In studies of the effects of cancer therapies, the 
frequent evaluative endpoints are survival and local 
control; however, it is imperative that clinical trials 
with palliative patients also have a q o l  focus when a 
cure is unattainable. We conducted a literature review 
to investigate the use of q o l  instrument tools in trials 
studying q o l  or symptom palliation of primary lung 
cancer or lung metastases through the use of radio-
therapy. We identified forty-three studies: nineteen 
used a q o l  tool, and twenty-four examined symptom 
palliation without the use of a q o l  instrument. The 
European Organization for Research and Treatment 
of Cancer (e o r t c) q l q -C30 survey was the most com-
monly used q o l  questionnaire (in thirteen of twenty 
trials). Of those thirteen studies, eight also incorpo-
rated the lung-specific q o l  survey e o r t c q l q -LC13 (or 
the e o r t c q l q -LC17). A second lung-specific survey, 
the Functional Assessment of Cancer Therapy–Lung 
(f a c t -L) was used in only two of the twenty trials. 
In total, only ten of forty-three trials (23%) used a 
lung-specific q o l  tool, suggesting that q o l  was of low 
priority as an endpoint and that measures created for 
lung cancer patients are underused. We encourage 
investigators in future trials to include specific q o l  
instruments such as the e o r t c q l q -LC13 or the f a c t -L 
for studies in palliative thoracic radiotherapy because 
those instruments provide a measure of q o l  specific 
to patients with lung cancer or lung metastases.
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“radiotherapy,” “radiation,” “external-beam irradia-
tion,” or “palliative radiotherapy.” This search was 
then combined with “quality of life” or “q o l ” and 
also “symptom palliation.” Relevant articles and 
abstracts were reviewed, and references from those 
sources were also manually searched for additional 
relevant publications.
2.2  Inclusion Criteria
To be included in the present literature review, articles 
had to meet these criteria:
•  Population: patients with a histologic, cytologic, 
or radiologic diagnosis of primary lung cancer or 
lung metastases
•  Intervention: external beam radiotherapy or en-
dobronchial brachytherapy in at least one study 
arm, with palliative intent
•  Types of studies: randomized trials, prospective 
or retrospective cohort studies
•  Endpoints: q o l  or symptom palliation as a primary 
or secondary endpoint or measured outcome
2.3  Exclusion Criteria
Articles were excluded if they met any of these criteria:
•  Article type: individual case report or review 
article
•  Language: publication in a language other than 
English
•  Intervention: no evaluation, in at least one arm, of 
external beam irradiation to the thorax or endo-
bronchial brachytherapy; or studies of interven-
tions with curative intent
•  Types of studies: focus on populations other than 
those with primary lung cancer or lung metastases
•  Endpoints: use of the Karnofsky performance 
status (k p s ) or other similar prognostic tools, 
correlation of q o l  with cost–utility, or test of the 
reliability or validity of a q o l  instrument
2.4  Data Extraction
We extracted the following information from the 
studies:
•  Primary and secondary outcomes
•  Radiotherapy treatment details
•  Type and number of q o l , symptom palliation, and 
additional tools, if any, used
•  Number of patients in each study arm
•  Median age and male:female ratio of the patients 
enrolled in the study
•  Median survival in each study arm
3.  RESULTS
We identified a total of forty-three trials that evalu-
ated, in at least one study arm, the use of palliative 
radiotherapy to the thorax, and that assessed q o l  or 
symptom palliation as a primary or secondary end-
point. Thirty studies (Table i) evaluated the treatment 
of patients with non-small-cell lung cancer (n s c l c ). 
Four studies (Table ii) involved patients who were 
treated with endobronchial brachytherapy alone or in 
addition to external-beam radiation. Brachytherapy 
differs from external-beam radiation in that it is a 
more localized form of radiation that limits toxicity in 
healthy tissue to the immediate vicinity of the radiated 
region 5. Another nine trials (Table iii) evaluated the 
use of palliative radiotherapy in patients with lung 
cancer of a histologic type other than n s c l c . The 
four identified studies that measured the difference 
in efficacy between endobronchial brachytherapy and 
external beam radiation 37-40 used both symptom pal-
liation and q o l  scores as a primary outcome.
In twenty of the identified studies, symptom 
palliation was used as a primary outcome 8,10,11,13, 
14,17,19,20,21,23,26,28–33,44,45,47. Ten trials used q o l  as a 
primary outcome 5,9,16,18,24,25,34,35,39,49, and six studies 
used both symptom palliation and q o l  together as a 
primary endpoint 22,27,37,38,40,48. Seven of the studies 
used neither symptom palliation nor q o l  as primary 
endpoints, but rather incorporated them as secondary 
outcomes 12,15,36,41–43,46. The four identified studies 
that measured the difference in efficacy between 
endobronchial brachytherapy and external beam 
radiation37–40 used both symptom palliation and q o l  
scores as primary outcomes.
3.1 QOL and Symptom Palliation Tools Used
A total of 11 tools were used to assess either q o l  or 
palliation of lung cancer–related symptoms; the fre-
quency of use of each tool is presented in Table iv. 
The most common q o l  tool used was the European 
Organization for Research and Treatment of Cancer 
(e o r t c) q l q -C30, a questionnaire that was created and 
validated to assess q o l  in individuals with any form 
of cancer. It has been translated into 81 languages and 
consists of 30 questions that encompass 5 functional 
scales: physical, role, cognitive, emotional, and social 
functioning 49. The e o r t c q l q -C30 also incorporates 3 
symptom scales: fatigue, pain, and nausea and vomit-
ing. The remaining items on the questionnaire cover 
other symptom-related events that are often described 
by cancer patients, including dyspnea, diarrhea, and 
loss of appetite, among others 48.
The e o r t c  q l q -C30 was used in fourteen of the 
forty-three studies identified in the search (32%), 
eight of which also used the lung cancer supplement, 
e o r t c  q l q -LC13. The e o r t c  q l q -LC13 is the latest 
version of a lung cancer–specific questionnaire that 
consists of questions concerning lung cancer symptoms SALVO et al.
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and the side effects of conventional treatments used 
for lung cancer 49. One trial used an older version of 
the lung-specific module, the e o r t c q l q -LC17, in 
addition to the general questionnaire 48.
The Functional Assessment of Cancer Therapy 
(f a c t ) q o l  tools constituted a second group used in 
the identified studies. Both the general questionnaire 
(f a c t -G) and the lung-specific questionnaire (f a c t -L) 
were used. Like the e o r t c q l q -C30, the f a c t -G is 
a general questionnaire that was developed for pa-
tients with any type of cancer. The f a c t -G covers 4 
dimensions of q o l : physical, social, emotional, and 
functional well-being 50. The f a c t -L is similar to the 
e o r t c q l q -LC13 because it includes additional ques-
tions that relate specifically to q o l  in patients with 
lung cancer. The f a c t -L was used in two studies, and 
the f a c t -G in one.
A third validated q o l  tool was used in one trial: 
the Spitzer q o l  Index. The Spitzer Index covers 5 di-
mensions of q o l : activity, daily living, health, support 
of family and friends, and outlook 51. It is not a lung 
cancer–specific questionnaire, however; and thus it 
does not incorporate questions directly related to the 
lung-cancer-specific patient population.
Study-designed questionnaires were the most 
prevalent tool used in the forty-three identified stud-
ies. A study-specific method of determining q o l  was 
used in three trials, and nineteen trials attempted to 
evaluate symptom palliation using a study-designed 
questionnaire. Table v shows a breakdown of the pro-
portion of studies using a validated q o l  or symptom 
palliation tool as compared with a study-designed 
tool. Study-designed instruments present a difficulty: 
drawing comparisons across studies is harder because 
the methods of measurement vary.
In five studies, a validated symptom palliation 
tool was used (the frequency of use can be seen in 
Table iv). The two general symptom tools used were 
the Hospital Anxiety and Depression Scale and the 
Rotterdam Symptom Checklist. The Rotterdam 
Symptom Checklist measures psychological and 
physical distress in cancer patients through the use 
of 38 items 52. The Hospital Anxiety and Depression 
Scale is a tool used to measure anxiety and depres-
sion levels using 14 statements based on a patient’s 
experience over the preceding week 53. One lung-
specific symptom tool—the Lung Cancer Symptom 
Scale—was used. The Lung Cancer Symptom Scale is 
a tool designed to measure 6 lung-specific symptoms 
and their effects on symptomatic distress, functional 
burden, and global quality of life 54,55.
Figure 1 outlines the overall picture of question-
naire use in the identified trials. Most of the trials 
(54%) measured symptom palliation alone; some 
measured both symptom palliation and q o l  (14%). 
The remaining trials measured q o l  only.
3.2  Performance Assessment
In forty studies (91%), the performance status of the 
subjects was measured in addition to q o l  or symptom 
palliation. Performance status was measured primarily 
as a prognostic factor (twenty of forty trials, 50%) 
or as part of the exclusion criteria (fourteen of forty 
trials, 35%). Only six studies used a performance 
f i g u r e  1  Questionnaire use in all identified studies.
t a b l e  iv  Frequency of instruments used in clinical trials 
measuring quality of life (q o l ) in patients with locally 
advanced lung cancer or lung metastases
Instrument  Frequency
European Organization for Research and Treatment of Cancer 
(e o r t c) 
  General cancer questionnaire (e o r t c q l q -C30)  13
  Lung cancer questionnaire (e o r t c q l q -LC13)  7
  Lung cancer questionnaire (e o r t c q l q -LC17)  1
Functional Assessment of Cancer Therapy (f a c t ) 
  General questionnaire (f a c t -G)  1
  Lung questionnaire (f a c t -L)  2
Spitzer q l q  Index  1
Hospital Anxiety and Depression Scale (h a d s )  5
Rotterdam Symptom Checklist (r s c l )  4
Study-designed q l q  questionnaire  3
Lung Cancer Symptom Scale (l c s s )  2
Study-designed symptom palliation questionnaire  19
 
t a b l e  v Use of validated or study-designed tools in forty-
three studies
  Questionnaire typea
  Symptom palliation  Quality of life
  (n)  (%)  (n)  (%)
Validated  9  21  16  37
Study-designed  21  49  3  7
Total  30  70  19  44
a  Six studies used both a q o l  and a symptom palliation tool.SALVO et al.
Cu r r e n t On C O l O g y —VO l u m e  16, nu m b e r 2
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scale as part of the assessment. The 3 most predominant 
performance status tools used were the World Health 
Organization performance status, the Eastern Coop-
erative Oncology Group scale, and the Karnofsky 
performance status (k p s ). Although performance 
scales are useful to determine the functional status of 
a patient, they are not adequate tools for measuring 
symptom palliation or q o l .
4.  DISCUSSION
In patients with terminal cancer, q o l  is a significant 
concept, and it is influenced by many factors, includ-
ing symptoms, functional level, coping strategies, and 
support systems 51. Common symptoms that influence 
a lung cancer patient’s q o l  include anxiety, depression, 
pain, fatigue, dyspnea, and cough 52. Because lung 
cancer is the leading cause of cancer death in men 
and the second-leading cause in women globally 2, it 
is important that q o l  is considered when caring for 
these patients.
Meaningful palliation refers to symptom relief 
and prolongation of good-quality survival in lung 
cancer patients 26. When treating a patient with pal-
liative intent, it is necessary to use tools that measure 
the intent of the treatment. For 86% of doctors from 
the United Kingdom, the United States, and Canada, 
the treatment of choice for patients with inoperable 
lung cancer is palliative radiotherapy 33. It is therefore 
important that, when considering the side effects of 
palliative radiotherapy as compared with the side ef-
fects of the lung cancer itself, trials investigating the 
use of palliative radiotherapy use a q o l  measure to 
determine the benefit of the treatment.
A total of twenty identified trials considering 
palliative radiotherapy for lung cancer included an 
evaluation of q o l . Of these trials, eleven used a tool 
that was specific to patients with lung cancer; the 
remaining nine used general q o l  questionnaires for 
cancer patients or a study-designed questionnaire. 
In thirty-one identified studies, the level of symp-
tom palliation, one aspect that contributes to a q o l  
measure, was assessed. This finding suggests that 
more trials should use a validated lung-specific tool 
when evaluating the outcome of palliative thoracic 
radiotherapy. Use of a validated, lung-specific tool 
will allow for comparisons between trials and will 
also increase the internal validity of individual stud-
ies. Two recommended lung-specific validated tools 
that would be beneficial for the measurement of q o l  
in trials evaluating palliative thoracic radiotherapy 
are the f a c t -L and the e o r t c q l q -LC13.
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